Proteogenomics

This is a highly innovative and novel partnership wherein, for the first time, three scientific service and technology industry leaders are dedicating and combining resources at this scale to advance proteogenomic research. This collaboration will overcome existing research challenges and accelerate progress in our understanding of human health and disease by helping our customers significantly expand and accelerate their multi-omics efforts. Rapid acquisition of data speeds development. This Consortium will provide new, highly-scaled and more comprehensive capabilities to develop and deploy novel biomarkers, drug candidates, and diagnostics.

We are entering a new era where progress is expected at pandemic speed. This collaboration and its commitment to proteogenomic accessibility will help accelerate many new discoveries for disease research. Sensitive detection and robust quantitation of biomarkers are foundational to Precision Medicine and support earlier and better diagnosis, along with more personalized and effective treatments.

We are thrilled to collaborate with Discovery Life Sciences and Sciex to bring unbiased, deep proteogenomics at scale to the market. Through our collaboration, we will empower genomics researchers to add unbiased, deep proteomics data to their studies, connecting genotype to phenotype, and enabling multi-omic studies of unprecedented resolution.